Studies for AZD4547 and BGJ389 revealed that patients with FGFR1 amplification (non-small cell lung cancer) or bearing FGFR3 mutations (bladder cancer) displayed a partial response to the therapy (47, 48). Here, FGFR3 is linked to non-small cell lung carcinoma.